During the annual event, volunteers advocated for the PASTEUR Act and the HELP Copays Act, two bipartisan pieces of legislation that could have substantial, positive impact on the CF community.
- About the CF Foundation
- Public Policy
- Drug Pipeline
- CFTR Modulators
- Our Research Approach
- Genetic Therapies
- Health Care Reform
- Clinical Trials
- Get Involved
- Our Advocacy Work
- North American CF Conference
- Cystic Fibrosis Foundation Therapeutics (CFFT)
- Care Centers
- Patient Assistance
- Infection Prevention and Control
- Patient Registry
- Coronavirus (COVID-19)
- Lung Transplantation
- In the Spotlight
- Diversity, Equity, and Inclusion
- Intro to CF
- Adult Care
- Clinician Resources
- Great Strides
- In Memoriam
- Researcher Resources
- Care Team
- CF-Related Complications
- CF Related Health Conditions
- Fertility and Reproductive Health
Two-thirds of people with cystic fibrosis in the U.S. experience debt, food insecurity, or housing issues.
Bipartisan legislation could help patients access necessary prescription drugs by potentially reducing the financial burden that results from complex and hard-to-navigate health insurance plans
The Foundation seeks to advance its mission by making improvements in key areas of health equity and outcomes and diverse workforce development.
The Foundation’s commitment to these principles will continue to be a cornerstone of the Foundation’s work to advance our mission in 2023.
Funding will support preclinical research and early-stage clinical trials
The Cystic Fibrosis Foundation’s investment will go toward conducting preclinical research on a novel gene delivery vehicle. If successful, this gene delivery method could overcome some of the biggest challenges to delivering a gene therapy into the lung cells of people with cystic fibrosis.
206 care center directors sign a letter citing clinical consequences if decision moves forward.
The physical footprint of the Cystic Fibrosis Foundation Therapeutics Lab grew by about a third this year, enabling startup companies and industry scientists to work and learn alongside lab staff.
The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.